Bicara chases Merus
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
EHA 2024 – Shattuck reassurances fall on deaf ears
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Immutep approaches Lag3 crunch time
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Shattuck gears up for go/no go year
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
TROP2 gets more crowded
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.
